Viking Therapeutics (VKTX) – Analysts’ Recent Ratings Updates

Several analysts have recently updated their ratings and price targets for Viking Therapeutics (NASDAQ: VKTX):

• 9/23/2026 – Viking Therapeutics had its price target raised by Truist Financial Corporation from $83.00 to $87.00. They now have a “buy” rating on the stock.
• 9/22/2026 – Viking Therapeutics was given a new $120.00 price target by Oppenheimer Holdings, Inc..
• 9/22/2026 – Viking Therapeutics had its “buy” rating reaffirmed by HC Wainwright.
• 9/22/2026 – Viking Therapeutics had its “overweight” rating reaffirmed by Morgan Stanley.
• 8/18/2026 – Viking Therapeutics was upgraded by Zacks Research from “strong sell” to “hold”.
• 8/11/2026 – Viking Therapeutics had its price target lowered by JPMorgan Chase & Co. from $75.00 to $65.00. They now have an “overweight” rating on the stock.
• 7/30/2026 – Viking Therapeutics had its price target raised by Canaccord Genuity Group Inc. from $107.00 to $114.00. They now have a “buy” rating on the stock.

Insider Transactions at Viking Therapeutics

In related news, CEO Brian Lian sold 148,517 shares of the stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $33.32, for a total value of $4,948,586.44. Following the sale, the chief executive officer owned 2,572,441 shares in the company, valued at approximately $85,713,734.12. This trade represents a 5.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Marianna Mancini sold 18,217 shares of the firm’s stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $33.47, for a total transaction of $609,722.99. Following the completion of the sale, the chief operating officer directly owned 422,760 shares in the company, valued at approximately $14,149,777.20. This trade represents a 4.13% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 187,951 shares of company stock valued at $6,268,442 over the last three months. Company insiders own 5.30% of the company’s stock.

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic and endocrine disorders. The company’s research programs target conditions including obesity, nonalcoholic steatohepatitis (NASH), metabolic dysfunction-associated steatohepatitis (MASH), dyslipidemia and other disorders involving hormone regulation and metabolism.

Viking’s lead program is VK2735, an investigational dual agonist of the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors being developed in injectable and oral formulations for obesity and related metabolic conditions.